At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
MGV354 ophthalmic suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Three Part, First-in-human, Randomized, Double-masked, Placebo-Controlled, Safety, Tolerability and Early Efficacy Study of MGV354 in Healthy Subjects and in Patients With Ocular Hypertension or Glaucoma
In Brief
A Phase 2 clinical trial evaluating MGV354 ophthalmic suspension and MGV354 placebo for Ocular Hypertension and Open-Angle Glaucoma. Completed, enrolled 191 participants.
Detailed Summary
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Open-Angle Glaucoma
Countries--
CollaboratorsNovartis Institute for BioMedical Research
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedApr 2016
Primary CompletionSep 2016
TodayJul 2026
First PostedApr 19, 2016
Enrollment StartMar 2, 2016
Primary CompletionSep 20, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.2 years ago
Interventions
MGV354 ophthalmic suspensiondrug
MGV354 placebodrug
Inactive ingredients used as placebo comparator